Cargando…
UK clinical guideline for the prevention and treatment of osteoporosis
SUMMARY: The National Osteoporosis Guideline Group (NOGG) has revised the UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. Accredited by NICE, this guideline is relevant for all healthcar...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979902/ https://www.ncbi.nlm.nih.gov/pubmed/35378630 http://dx.doi.org/10.1007/s11657-022-01061-5 |
_version_ | 1784681278895816704 |
---|---|
author | Gregson, Celia L. Armstrong, David J. Bowden, Jean Cooper, Cyrus Edwards, John Gittoes, Neil J. L. Harvey, Nicholas Kanis, John Leyland, Sarah Low, Rebecca McCloskey, Eugene Moss, Katie Parker, Jane Paskins, Zoe Poole, Kenneth Reid, David M. Stone, Mike Thomson, Julia Vine, Nic Compston, Juliet |
author_facet | Gregson, Celia L. Armstrong, David J. Bowden, Jean Cooper, Cyrus Edwards, John Gittoes, Neil J. L. Harvey, Nicholas Kanis, John Leyland, Sarah Low, Rebecca McCloskey, Eugene Moss, Katie Parker, Jane Paskins, Zoe Poole, Kenneth Reid, David M. Stone, Mike Thomson, Julia Vine, Nic Compston, Juliet |
author_sort | Gregson, Celia L. |
collection | PubMed |
description | SUMMARY: The National Osteoporosis Guideline Group (NOGG) has revised the UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. Accredited by NICE, this guideline is relevant for all healthcare professionals involved in osteoporosis management. INTRODUCTION: The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013 and 2017. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. METHODS: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. RESULTS: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, and models of care for fracture prevention. Recommendations are made for training; service leads and commissioners of healthcare; and for review criteria for audit and quality improvement. CONCLUSION: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management. This position paper has been endorsed by the International Osteoporosis Foundation and by the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. |
format | Online Article Text |
id | pubmed-8979902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-89799022022-04-22 UK clinical guideline for the prevention and treatment of osteoporosis Gregson, Celia L. Armstrong, David J. Bowden, Jean Cooper, Cyrus Edwards, John Gittoes, Neil J. L. Harvey, Nicholas Kanis, John Leyland, Sarah Low, Rebecca McCloskey, Eugene Moss, Katie Parker, Jane Paskins, Zoe Poole, Kenneth Reid, David M. Stone, Mike Thomson, Julia Vine, Nic Compston, Juliet Arch Osteoporos Position Paper SUMMARY: The National Osteoporosis Guideline Group (NOGG) has revised the UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. Accredited by NICE, this guideline is relevant for all healthcare professionals involved in osteoporosis management. INTRODUCTION: The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013 and 2017. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. METHODS: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. RESULTS: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, and models of care for fracture prevention. Recommendations are made for training; service leads and commissioners of healthcare; and for review criteria for audit and quality improvement. CONCLUSION: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management. This position paper has been endorsed by the International Osteoporosis Foundation and by the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Springer London 2022-04-05 2022 /pmc/articles/PMC8979902/ /pubmed/35378630 http://dx.doi.org/10.1007/s11657-022-01061-5 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Position Paper Gregson, Celia L. Armstrong, David J. Bowden, Jean Cooper, Cyrus Edwards, John Gittoes, Neil J. L. Harvey, Nicholas Kanis, John Leyland, Sarah Low, Rebecca McCloskey, Eugene Moss, Katie Parker, Jane Paskins, Zoe Poole, Kenneth Reid, David M. Stone, Mike Thomson, Julia Vine, Nic Compston, Juliet UK clinical guideline for the prevention and treatment of osteoporosis |
title | UK clinical guideline for the prevention and treatment of osteoporosis |
title_full | UK clinical guideline for the prevention and treatment of osteoporosis |
title_fullStr | UK clinical guideline for the prevention and treatment of osteoporosis |
title_full_unstemmed | UK clinical guideline for the prevention and treatment of osteoporosis |
title_short | UK clinical guideline for the prevention and treatment of osteoporosis |
title_sort | uk clinical guideline for the prevention and treatment of osteoporosis |
topic | Position Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979902/ https://www.ncbi.nlm.nih.gov/pubmed/35378630 http://dx.doi.org/10.1007/s11657-022-01061-5 |
work_keys_str_mv | AT gregsoncelial ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT armstrongdavidj ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT bowdenjean ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT coopercyrus ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT edwardsjohn ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT gittoesneiljl ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT harveynicholas ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT kanisjohn ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT leylandsarah ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT lowrebecca ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT mccloskeyeugene ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT mosskatie ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT parkerjane ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT paskinszoe ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT poolekenneth ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT reiddavidm ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT stonemike ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT thomsonjulia ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT vinenic ukclinicalguidelineforthepreventionandtreatmentofosteoporosis AT compstonjuliet ukclinicalguidelineforthepreventionandtreatmentofosteoporosis |